AlphaCentric Advisors LLC bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $1,138,000.
Other large investors have also recently bought and sold shares of the company. Mondrian Investment Partners LTD grew its holdings in shares of Takeda Pharmaceutical by 47.9% during the first quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after purchasing an additional 3,912,569 shares in the last quarter. Millennium Management LLC grew its position in Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after acquiring an additional 2,023,707 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after acquiring an additional 134,407 shares in the last quarter. Cowen AND Company LLC bought a new stake in shares of Takeda Pharmaceutical in the 2nd quarter worth approximately $6,866,000. Finally, Sei Investments Co. grew its holdings in shares of Takeda Pharmaceutical by 6.7% during the 1st quarter. Sei Investments Co. now owns 372,975 shares of the company’s stock valued at $5,181,000 after purchasing an additional 23,525 shares during the last quarter. 9.17% of the stock is owned by institutional investors.
Takeda Pharmaceutical Stock Performance
NYSE TAK opened at $14.05 on Tuesday. The firm has a market cap of $44.71 billion, a price-to-earnings ratio of 24.22, a PEG ratio of 0.27 and a beta of 0.54. The company has a 50-day simple moving average of $14.46 and a two-hundred day simple moving average of $13.80. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
- Five stocks we like better than Takeda Pharmaceutical
- Top Stocks Investing in 5G Technology
- Mobileye’s Recovery Steadily Gains Traction with Novel AI
- Stock Analyst Ratings and Canadian Analyst Ratings
- Options Traders Bet Big on These 3 Tech Stocks
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Rise of AI Agents vs. RPA Bots: 3 Stocks to Watch Now
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.